Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients-Reference-Cited by-同舟云学术

Polymyxin B Pharmacokinetics in Adult Cystic Fibrosis Patients

Published:2018-07 Issue:7 Volume:38 Page:730-738
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Avedissian Sean N.¹^ORCID,Miglis Cristina¹,Kubin Christine J.²³,Rhodes Nathaniel J.¹^ORCID,Yin Michael T.³,Cremers Serge⁴,Prickett Michelle⁵,Scheetz Marc H.¹^ORCID

Affiliation:

1. Department of Pharmacy Practice; Midwestern University Chicago College of Pharmacy; Downers Grove Illinois

2. Department of Pharmacy; NewYork-Presbyterian Hospital; New York City New York

3. Division of Infectious Diseases; Columbia University Irving Medical Center; New York City New York

4. Department of Pathology and Cell Biology; Columbia University Irving Medical Center; New York City New York

5. Feinberg School of Medicine; Northwestern University; Chicago Illinois

Publisher

Wiley

Subject

Pharmacology (medical)

Reference40 articles.

1. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2014

2. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?;Berger;Clin Rev Allergy,1991

3. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis;Conway;Am J Respir Med,2003

4. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients;Garonzik;Antimicrob Agents Chemother,2011

5. Nephrotoxicity in patients with and without cystic fibrosis treated with polymyxin B compared to colistin;Crass;Antimicrob Agents Chemother,2017

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation;Xenobiotica;2024-07-08

2. How can polymyxin B be dosed based on current pharmacokinetic knowledge?;European Journal of Clinical Pharmacology;2024-06-07

3. A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database;Expert Opinion on Drug Safety;2024-05

4. A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction;Journal of Pharmacokinetics and Pharmacodynamics;2024-04-16

5. Pharmacokinetics of polymyxin B in different populations: a systematic review;European Journal of Clinical Pharmacology;2024-03-14